SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northfield Lab(NFLD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: erbob who wrote (71)7/12/1998 1:44:00 PM
From: Merritt  Read Replies (1) of 148
 
erbob, nice to get your input. Biopure's trying to do an end run with Hemopure, IMHO, probably hoping the presence of C.E.Koop, former Surgeon General of U.S, on their Board of Directors will have some clout with the FDA. Maybe it will, what with the present gov't's record on ethics, but it shouldn't allow them to bypass more extensive testing. They appear to be trying to get their product OK'd for a specific application (cardiac surgery) where everything's done under tightly controlled conditions, so that it can then be used off-label for other applications. Even if they succeed, it doesn't mean the end for NFLD, though. As you indicate, it doesn't seem to hold much value for trauma patients in need of large infusions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News